Agios Pharmaceuticals Financial Statements (AGIO)
|
|
|
|
Report date
|
|
|
19.02.2020 |
25.02.2021 |
24.02.2022 |
23.02.2023 |
15.02.2024 |
|
31.10.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
117.9 |
203.2 |
0.000 |
14.2 |
26.8 |
|
32.9 |
|
Operating Income, bln rub |
|
|
-426.3 |
-316.1 |
-378.4 |
-389.0 |
-391.5 |
|
-407.0 |
|
EBITDA, bln rub |
? |
|
-394.9 |
-326.1 |
-337.7 |
-380.5 |
-384.9 |
|
702.6 |
|
Net profit, bln rub |
? |
|
-396.6 |
-335.2 |
1 605 |
-74.6 |
-352.1 |
|
674.3 |
|
|
OCF, bln rub |
? |
|
-370.6 |
-290.8 |
-407.3 |
-309.5 |
-296.1 |
|
-329.2 |
|
CAPEX, bln rub |
? |
|
12.2 |
14.9 |
5.74 |
4.88 |
0.999 |
|
0.952 |
|
FCF, bln rub |
? |
|
-382.8 |
-305.7 |
-413.1 |
-314.4 |
-297.1 |
|
-330.1 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
542.9 |
516.5 |
378.4 |
401.6 |
408.8 |
|
432.0 |
|
Cost of production, bln rub |
|
|
1.32 |
2.81 |
18.8 |
1.70 |
9.50 |
|
7.84 |
|
R&D, bln rub |
|
|
410.9 |
367.5 |
257.0 |
279.9 |
288.9 |
|
291.6 |
|
Interest expenses, bln rub |
|
|
0.000 |
17.8 |
0.000 |
12.8 |
0.000 |
|
0.000 |
|
|
Assets, bln rub |
|
|
890.7 |
853.0 |
1 438 |
1 239 |
937.1 |
|
1 792 |
|
Net Assets, bln rub |
? |
|
640.5 |
399.5 |
1 292 |
1 101 |
811.0 |
|
1 627 |
|
Debt, bln rub |
|
|
113.7 |
105.2 |
97.1 |
85.7 |
72.0 |
|
60.8 |
|
Cash, bln rub |
|
|
564.9 |
670.5 |
1 286 |
1 097 |
776.9 |
|
1 005 |
|
Net debt, bln rub |
|
|
-451.2 |
-565.3 |
-1 189 |
-1 011 |
-704.9 |
|
-943.9 |
|
|
Ordinary share price, rub |
|
|
47.8 |
43.3 |
32.9 |
28.1 |
22.3 |
|
21.0 |
|
Number of ordinary shares, mln |
|
|
60.0 |
69.0 |
60.4 |
54.8 |
55.7 |
|
56.9 |
|
|
Market cap, bln rub |
|
|
2 865 |
2 990 |
1 987 |
1 538 |
1 239 |
|
1 195 |
|
EV, bln rub |
? |
|
2 414 |
2 424 |
798 |
527 |
534 |
|
251 |
|
Book value, bln rub |
|
|
641 |
400 |
1 292 |
1 101 |
811 |
|
1 627 |
|
|
EPS, rub |
? |
|
-6.61 |
-4.86 |
26.5 |
-1.36 |
-6.33 |
|
11.8 |
|
FCF/share, rub |
|
|
-6.38 |
-4.43 |
-6.83 |
-5.74 |
-5.34 |
|
-5.80 |
|
BV/share, rub |
|
|
10.7 |
5.79 |
21.4 |
20.1 |
14.6 |
|
28.6 |
|
|
EBITDA margin, % |
? |
|
-334.9% |
-160.5% |
|
-2 672% |
-1 435% |
|
2 137% |
|
Net margin, % |
? |
|
-336.4% |
-165.0% |
|
-523.6% |
-1 313% |
|
2 051% |
|
FCF yield, % |
? |
|
-13.4% |
-10.2% |
-20.8% |
-20.4% |
-24.0% |
|
-27.6% |
|
ROE, % |
? |
|
-61.9% |
-83.9% |
124.2% |
-6.77% |
-43.4% |
|
41.5% |
|
ROA, % |
? |
|
-44.5% |
-39.3% |
111.6% |
-6.02% |
-37.6% |
|
37.6% |
|
|
P/E |
? |
|
-7.22 |
-8.92 |
1.24 |
-20.6 |
-3.52 |
|
1.77 |
|
P/FCF |
|
|
-7.48 |
-9.78 |
-4.81 |
-4.89 |
-4.17 |
|
-3.62 |
|
P/S |
? |
|
24.3 |
14.7 |
|
108.0 |
46.2 |
|
36.4 |
|
P/BV |
? |
|
4.47 |
7.48 |
1.54 |
1.40 |
1.53 |
|
0.73 |
|
EV/EBITDA |
? |
|
-6.11 |
-7.43 |
-2.36 |
-1.39 |
-1.39 |
|
0.36 |
|
Debt/EBITDA |
|
|
1.14 |
1.73 |
3.52 |
2.66 |
1.83 |
|
-1.34 |
|
|
R&D/CAPEX, % |
|
|
3 376% |
2 465% |
4 476% |
5 735% |
28 919% |
|
30 632% |
|
|
CAPEX/Revenue, % |
|
|
10.3% |
7.34% |
|
34.3% |
3.72% |
|
2.90% |
|
| Agios Pharmaceuticals shareholders |
